Carmen Saiz Guisasola/LinkedIn
May 7, 2025, 18:04
Carmen Saiz Guisasola: It Was Honour to Witness the Presentation of the EMBRACE-II Results This Morning at ESTRO 2025
Carmen Saiz Guisasola, Specialist Physician at HM Hospitales, shared on LinkedIn:
“Huge congratulations to all the EMBRACE collaborators for this outstanding achievement!
It was a true honour to witness the presentation of the EMBRACE-II results this morning at ESTRO2025.
EMBRACE-II: The new standard of care for locally advanced cervical cancer
A beautifully executed protocol combining:
- IGRT/IMRT (45 Gy) with tight margins and risk-adapted planning
- Lymph node SIB (57 Gy)
- MRI-guided adaptive brachytherapy (IC/IS)
- Multi-parametric planning balancing CTVHR D90 ≥90 Gy & OAR limits
- Cisplatin-based chemotherapy & timely delivery (42–45 days)
Results (3y):
- Local control: 93%
- Nodal control: 91%
- Distant control: 88%
- Overall survival: 87%
- Disease-specific survival: 89%
- Severe late toxicity (G3–5): only 8.9% (G4 <1%, G5 <0.2%)
Compared to EMBRACE-I:
- Disease progression ↓ 17%
- Death ↓ 25%
- G3–G5 morbidity ↓ 45%
A protocol that is valid, reproducible and predictive – truly practice-defining!
Also, kudos to the FAST-FORWARD team for showing that:
26 Gy in 5 fractions is safe and non-inferior to 40 Gy in 15 for adjuvant axillary RT:
- No extra arm/hand swelling
- No brachial plexopathy
- Low recurrence expected
Clinical excellence advancing patient care and quality of life.”
See more posts featuring ESTRO 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 8, 2025, 00:17
May 7, 2025, 23:18
May 7, 2025, 22:49